Lincoln Pharmaceuticals Ltd reports Q2 FY27 revenue of ₹191.35 crore, up 17.1% year-on-year
- EBITDA was ₹33.22 crore, up 1.7% YoY; margin was 17.4%, versus 20.0% a year earlier.
- Net profit stood at ₹20.43 crore, up 2.2% YoY; no exceptional items were reported.
- Auditors’ limited reviews noted no indication of material misstatement; the consolidated review flagged that a subsidiary’s interim information was not auditor-reviewed.